Physician profile
Annette Goodman
NPI 1912106469
$3,165.61
in general payments reported to CMS, 2019-2025
28 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.42 · 2020: $106 · 2021: $196 · 2023: $151 · 2024: $798 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $331.88 | 2024-2025 | Vyepti |
| Biogen, INC. | $326.05 | 2021-2025 | Tysabri, Vumerity |
| Neurelis, INC. | $299.59 | 2024-2025 | Valtoco |
| Abbvie INC. | $282.09 | 2024-2025 | |
| Ucb, INC. | $266.01 | 2024-2025 | Rystiggo, Briviact, Nayzilam |
| Pfizer INC. | $210.82 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $152.63 | 2020-2025 | Ultomiris |
| Abbott Laboratories | $151.20 | 2023 | Infinity |
| Novartis Pharmaceuticals Corporation | $140.38 | 2019-2025 | |
| Argenx US, INC. | $111.02 | 2024-2025 | Vyvgart |
| Tg Therapeutics, INC. | $107.22 | 2025 | |
| Neurocrine Biosciences, INC. | $107.09 | 2024-2025 | Ingrezza |
| Genentech USA, INC. | $100.83 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Sunovion Pharmaceuticals INC. | $93.05 | 2019-2021 | |
| Ardelyx, INC. | $68.12 | 2024-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $53.07 | 2025 | Acthar |
| Jazz Pharmaceuticals INC. | $51.45 | 2025 | |
| Genzyme Corporation | $47.44 | 2025 | |
| Livanova USA, INC. | $37.98 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Otsuka America Pharmaceutical, INC. | $37.63 | 2025 | Rexulti |
| Grifols USA, LLC | $30.79 | 2025 | Gamunex-C |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.90 | 2024 | Lifevest |
| Ipsen Biopharmaceuticals, INC | $26.47 | 2024 | Dysport |
| Eisai INC. | $24.48 | 2025 | |
| Redhill Biopharma INC. | $24.34 | 2025 | Talicia |
| Merz Pharmaceuticals, LLC | $23.82 | 2025 | Xeomin, Inbrija |
| Novo Nordisk INC | $18.57 | 2025 | Wegovy |
| Axsome Therapeutics, INC. | $14.69 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.